CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：DC-CTL targeting carbonic anhydrase IX gene combined with iAPA therapy in the treatment of renal cell carcinoma.
DC-CTL targeting carbonic anhydrase IX gene combined with iAPA therapy in the treatment of renal cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现可能为 RCC 提示一种新的治疗选择。
在肿瘤免疫治疗中递送特异性抗原时，通常使用肿瘤细胞裂解物致敏树突状细胞（DCs）。然而，裂解物免疫原性低，且含有多种非肿瘤相关抗原，可能诱发自身免疫性疾病。肿瘤抗原肽具有高特异性，但价格昂贵，且半衰期短限制了其临床应用。
本研究利用腺病毒将碳酸酐酶IX（CA9）基因导入DC，以产生针对肾细胞癌（RCC）的特异性，RCC是人类最常见的占位性病变。同时采用抑制抗原呈递衰减因子（iAPA）技术增强DC的递送能力。最后，将DC与细胞毒性T淋巴细胞（CTL）共培养，并评估其抗肿瘤效果。
结果显示，CA9-DC-CTLs对CA9阳性细胞具有高度特异性，并且在体外和体内均显示出比GFP-DC-CTLs更强的抗肿瘤活性。
In this study, we used adenovirus to transfer the carbonic anhydrase IX (CA9) gene into DCs to generate specificity to renal cell carcinoma (RCC) which is the most common space-occupying lesion in humans. Inhibition of antigen presentation attenuators (iAPA) technology was also used to enhance the DC delivery capacity. Finally, DCs were co-cultured with cytotoxic T-lymphocytes (CTLs) and the anti-tumor effects were evaluated.
The results showed that the CA9-DC-CTLs possessed a high specificity to CA9-positive cells and showed stronger anti-tumor activity than GFP-DC-CTLs both in vitro and in vivo . DISCUSSION: These findings may suggest a novel treatment option for RCC.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
